Fasudil

Drug Profile

Fasudil

Alternative Names: AT 877; Chuanwei; Eril; Eril Injection S; HA 1077

Latest Information Update: 22 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Asahi Kasei
  • Developer Asahi Kasei; Asahi Kasei Pharma Corp; Eisai Co Ltd; Tianjin Chase Sun Pharmaceutical
  • Class Amines; Anti-ischaemics; Ischaemic heart disorder therapies; Isoquinolines; Small molecules; Sulfonamides
  • Mechanism of Action Calcium channel antagonists; Protein kinase C inhibitors; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cerebral ischaemia; Cerebral vasospasm
  • Clinical Phase Unknown Pulmonary arterial hypertension
  • Discontinued Angina pectoris; Atherosclerosis; HIV-1 infections; Intracranial thrombosis

Most Recent Events

  • 27 Dec 2013 Discontinued - Preclinical for Cerebral ischaemia in South Korea (IV)
  • 01 Jul 2013 Launched for Cerebral vasospasm in China (IV)
  • 31 May 2013 Phase-II clinical trials in Pulmonary arterial hypertension in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top